New York S 6925: Prohibits freight trains in excess of eight thousand five hundred feet in length
Status: RECOMMIT, ENACTING CLAUSE STRICKEN (as of 2024-05-06)
State: New York · Session: 2023-2024 · Bill: S 6925
Sponsors: Timothy M. Kennedy, Joseph P. Addabbo Jr., Lea Webb, Rachel May
Bill Text
Bill Search and Legislative Information | New York State Assembly • • • • • • • • Skip to main content New York State Assembly Speaker Carl E. Heastie --> --> --> • Assembly Members • Legislative Info • Public Hearings • Speaker's Press • Assembly Reports • Committees & More • Bill Search Home • Laws • Legislative Calendar • Public Hearing Schedule • Assembly Calendars • Assembly Committee Agenda Javascript must be enabled to properly view this page. - This bill is not active in this session. Bill No.: • Summary • Actions • Committee Votes • Floor Votes • Memo • Text • LFIN • Chamber Video/Transcript S06925 Summary: BILL NOS06925   SAME ASSAME AS A03833   SPONSORHOYLMAN-SIGAL   COSPNSR   MLTSPNSR   Amd §§3216, 3221 & 4303, Ins L; amd §365-a, Soc Serv L   Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient. Go to top S06925 Actions: BILL NOS06925   03/27/2025REFERRED TO INSURANCE Go to topS06925 Committee Votes: Go to topS06925 Floor Votes: There are no Assembly votes for this bill in this legislative session. Go to topS06925 Text: STATE OF NEW YORK ________________________________________________________________________ 6925 2025-2026 Regular Sessions IN SENATE March 27, 2025 ___________ Introduced by Sen. HOYLMAN-SIGAL -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance AN ACT to amend the insurance law and the social services law, in relation to capping cost sharing for antiviral COVID-19 therapeutics The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Subsection (i) of section 3216 of the insurance law is 2 amended by adding a new paragraph 40 to read as follows: 3 (40) (A) Every policy that provides coverage for prescription drugs 4 shall provide coverage for antiviral therapeutics approved or granted 5 emergency use authorization by the food and drug administration for the 6 treatment of COVID-19 when prescribed by a licensed health care provider 7 legally authorized to prescribe under title eight of the education law. 8 (B) Coverage under this paragraph shall not be subject to annual 9 deductibles or coinsurance, provided, however, that an insured who is 10 eligible for and able to obtain prescribed antiviral therapeutics at no 11 cost or reduced cost under a manufacturer or government program may be 12 required to use such program before using coverage required pursuant to 13 this paragraph. 14 § 2. Subsection (k) of section 3221 of the insurance law is amended by 15 adding a new paragraph 24 to read as follows: 16 (24) (A) Every group or blanket policy delivered or issued for deliv- 17 ery in this state that provides coverage for prescription drugs shall 18 provide coverage for antiviral therapeutics approved or granted emergen- 19 cy use authorization by the food and drug administration for the treat- 20 ment of COVID-19 when prescribed by a licensed health care provider 21 legally authorized to prescribe under title eight of the education law. 22 (B) Coverage under this paragraph shall not be subject to annual 23 deductibles or coinsurance, provided, however, that an insured who is 24 eligible for and able to obtain prescribed antiviral therapeutics at no 25 cost or reduced cost under a manufacturer or government program may be EXPLANATION--Matter in italics (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD07443-01-5 S. 6925 2 1 required to use such program before using coverage required pursuant to 2 this paragraph. 3 § 3. Section 4303 of the insurance law is amended by adding a new 4 subsection (ww) to read as follows: 5 (ww) (1) Every contract issued by a medical expense indemnity corpo- 6 ration, a hospital service corporation, or a health service corporation 7 that provides coverage for prescription drugs shall provide coverage for 8 antiviral therapeutics approved or granted emergency use authorization 9 by the food and drug administration for the treatment of COVID-19 when 10 prescribed by a licensed health care provider legally authorized to 11 prescribe under title eight of the education law. 12 (2) Coverage under this subsection shall not be subject to annual 13 deductibles or coinsurance, provided, however, that an insured who is 14 eligible for and able to obtain prescribed antiviral therapeutics at no 15 cost or reduced cost under a manufacturer or government program may be 16 required to use such program before using coverage required pursuant to 17 this subsection.
View New York S 6925 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.